MCID: LKM004
MIFTS: 38

Leukemia, B-Cell, Chronic

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Leukemia, B-Cell, Chronic

MalaCards integrated aliases for Leukemia, B-Cell, Chronic:

Name: Leukemia, B-Cell, Chronic 54
Chronic Lymphocytic Leukemia 74
Chronic B-Cell Leukemia 54

Classifications:



External Ids:

UMLS 74 C0023434

Summaries for Leukemia, B-Cell, Chronic

MalaCards based summary : Leukemia, B-Cell, Chronic, also known as chronic lymphocytic leukemia, is related to leukemia, chronic lymphocytic and leukemia, chronic lymphocytic 2, and has symptoms including fatigue, angina pectoris and edema. An important gene associated with Leukemia, B-Cell, Chronic is ATM (ATM Serine/Threonine Kinase). The drugs Adenosine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Leukemia, B-Cell, Chronic

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Leukemia, B-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 12.1
2 leukemia, chronic lymphocytic 2 10.4
3 lymphocytic leukemia 10.3
4 leukemia 10.2
5 hairy cell leukemia 10.1
6 lymphoid leukemia 9.9
7 myeloid leukemia 9.9

Graphical network of the top 20 diseases related to Leukemia, B-Cell, Chronic:



Diseases related to Leukemia, B-Cell, Chronic

Symptoms & Phenotypes for Leukemia, B-Cell, Chronic

UMLS symptoms related to Leukemia, B-Cell, Chronic:


fatigue, angina pectoris, edema, chest pain

Drugs & Therapeutics for Leukemia, B-Cell, Chronic

Drugs for Leukemia, B-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 613)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
4
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
5
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
8
ofatumumab Approved Phase 4,Phase 3,Phase 2,Phase 1 679818-59-8 6918251
9
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
10
leucovorin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 58-05-9 6006 143
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
12
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
13
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
14
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
15
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
16
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
17
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 59-30-3 6037
19
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
20 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Bendamustine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
36 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
37 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Folate Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
42 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Methylprednisolone Acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Vitamin B9 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
45 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Folic Acid Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1794)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
4 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
6 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
7 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
8 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
9 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
10 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
11 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
12 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
13 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
14 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
15 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
16 Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
17 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
19 The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3 Cholecalciferol;oleum neutralicum
20 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
21 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
22 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
23 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
24 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
25 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
26 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
27 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
28 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
29 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
30 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
31 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
32 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
33 Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
34 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
35 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
36 Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01659021 Phase 3 Idelalisib;Ofatumumab
37 Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
38 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
39 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
40 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
41 Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
42 A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
43 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
44 A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
45 A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
46 Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
47 Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia Completed NCT00281892 Phase 3 Fludarabine mono
48 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
49 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
50 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3

Search NIH Clinical Center for Leukemia, B-Cell, Chronic

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Leukemia, B-Cell, Chronic

Anatomical Context for Leukemia, B-Cell, Chronic

MalaCards organs/tissues related to Leukemia, B-Cell, Chronic:

42
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Kidney, Nk Cells

Publications for Leukemia, B-Cell, Chronic

Articles related to Leukemia, B-Cell, Chronic:

(show top 50) (show all 5554)
# Title Authors Year
1
Concurrent cerebral aspergillosis and abdominal mucormycosis during Ibrutinib therapy for chronic lymphocytic leukemia. ( 30703527 )
2019
2
Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia. ( 30899641 )
2019
3
Cutaneous composite lymphoma consisting of chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma: a unique entity and a putative pathological mechanism for cutaneous composite lymphomas. ( 30650954 )
2019
4
Hairy cell leukemia coexistent with chronic lymphocytic leukemia. ( 30872271 )
2019
5
Durable Leukemic Remission and Autologous Marrow Recovery with Random Chromosomal Abnormalities after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. ( 30719361 )
2019
6
Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia. ( 30792201 )
2019
7
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib. ( 30579570 )
2019
8
Atypical presentation of cutaneous herpes simplex virus in a patient with chronic lymphocytic leukemia. ( 30726479 )
2019
9
Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells. ( 30886745 )
2019
10
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by a three-year rituximab maintenance. ( 30890600 )
2019
11
Multiparametric analysis of CD8+ T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy. ( 30906665 )
2019
12
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. ( 30911113 )
2019
13
Ibrutinib for the treatment of chronic lymphocytic leukemia. ( 30916599 )
2019
14
Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance). ( 30916608 )
2019
15
Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells. ( 30842145 )
2019
16
Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature. ( 30842245 )
2019
17
Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial. ( 30843659 )
2019
18
Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma. ( 30843894 )
2019
19
Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. ( 30848394 )
2019
20
Fever and rash in an adult: Varicella re-infection in conjunction with newly diagnosed chronic lymphocytic leukemia. ( 30849382 )
2019
21
Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks. ( 30852300 )
2019
22
Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy? ( 30858962 )
2019
23
Accelerating CAR therapy in CLL: The development and challenges of CAR T cell therapy for chronic lymphocytic leukemia. ( 30861173 )
2019
24
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. ( 30862645 )
2019
25
Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors. ( 30864706 )
2019
26
CD81 Expression in the Differential Diagnosis of Chronic Lymphocytic Leukemia. ( 30868852 )
2019
27
Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia. ( 30870839 )
2019
28
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. ( 30872781 )
2019
29
1q23.1 homozygous deletion and downregulation of Fc receptor-like family genes confer poor prognosis in chronic lymphocytic leukemia. ( 30877410 )
2019
30
Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. ( 30797139 )
2019
31
Application of a Sequential Multiple Assignment Randomized Trial (SMART) Design in Older Patients with Chronic Lymphocytic Leukemia. ( 30799502 )
2019
32
The prevalence and prognostic significance of autoimmune cytopenias in a cohort of Egyptian patients with chronic lymphocytic leukemia. ( 30802421 )
2019
33
Lymphomatoid Granulomatosis in a Patient with Chronic Lymphocytic Leukemia and Rapidly Progressing Peribronchovascular Pulmonary Infiltrates. ( 30805241 )
2019
34
Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options. ( 30807655 )
2019
35
DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia patients and chromosomal gains. ( 30807786 )
2019
36
Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma. ( 30808814 )
2019
37
Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees. ( 30808891 )
2019
38
Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. ( 30814061 )
2019
39
p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. ( 30819907 )
2019
40
Study of microRNA Profile as a Molecular Biomarker in Egyptian Chronic Lymphocytic Leukemia. ( 30828154 )
2019
41
Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns. ( 30828568 )
2019
42
Abnormalities in chemokine receptor recycling in chronic lymphocytic leukemia. ( 30830241 )
2019
43
Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia. ( 30839345 )
2019
44
Low-Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab (LD-FCR) Is an Effective and Safe Regimen for Elderly Untreated Patients with Chronic Lymphocytic Leukemia: The Israeli CLL Study Group Experience. ( 30756414 )
2019
45
MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest. ( 30760844 )
2019
46
Chronic lymphocytic leukemia with deletion 17p: An Indian scenario. ( 30766851 )
2019
47
Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis. ( 30767298 )
2019
48
Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? ( 30771875 )
2019
49
The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature. ( 30773964 )
2019
50
Paraneoplastic Eosinophilic Dermatosis in a Case of Chronic Lymphocytic Leukemia. ( 30775302 )
2019

Variations for Leukemia, B-Cell, Chronic

Expression for Leukemia, B-Cell, Chronic

Search GEO for disease gene expression data for Leukemia, B-Cell, Chronic.

Pathways for Leukemia, B-Cell, Chronic

GO Terms for Leukemia, B-Cell, Chronic

Sources for Leukemia, B-Cell, Chronic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....